<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576238</url>
  </required_header>
  <id_info>
    <org_study_id>ACO/02/08</org_study_id>
    <nct_id>NCT00576238</nct_id>
  </id_info>
  <brief_title>Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser</brief_title>
  <official_title>A Multi Centre, Parallel, Randomised Study of the Skin Tolerance of Betamethasone Creams on Atopic Eczema and the Influence of Moisturiser Treatment on the Recurrence of Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACO Hud Nordic AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACO Hud Nordic AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical steroid creams as well as moisturizing creams are important parts of the treatment
      strategy of atopic eczema. This study aims to investigate the tolerance of a new strong
      steroid cream in comparison to an already marketed reference cream with equal amount of
      active but with different cream vehicle. The second part of the study will investigate the
      possible preventative property of a moisturizing cream on skin that has been previously
      cleared from eczema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study the compatibility of the skin with the new formulation in comparison to the reference medication.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To study the effect of maintenance therapy with an emollient cream on the possible recurrence of atopic eczema.</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study cosmetic acceptance of the corticosteroids</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the safety of corticosteroid treatment.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the safety of maintenance treatment.</measure>
    <time_frame>Up to 6 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Atopic Eczema</condition>
  <arm_group>
    <arm_group_label>1:1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 - eczema treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1:2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 1 - eczema treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 - maintenance treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Part 2 - maintenance treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betamethasone valerate</intervention_name>
    <description>Topical application according to a fixed schedule for three weeks</description>
    <arm_group_label>1:1</arm_group_label>
    <other_name>Betnoderm 0,1 % kräm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betamethasone valerate</intervention_name>
    <description>Topical application according to a fixed schedule for three weeks</description>
    <arm_group_label>1:2</arm_group_label>
    <other_name>Betnovat kräm 0,1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urea</intervention_name>
    <description>Topical application twice daily for up to 6 months</description>
    <arm_group_label>2:1</arm_group_label>
    <other_name>Canoderm kräm 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and males between 18 and 65 years of age

          -  Caucasian

          -  AD according to the criteria of Hanifin and Rajka (12) with eczematous lesions
             corresponding to an Atopic Dermatitis Severity Index (ADSI) (13) score of at least 6
             on any of the following areas: arms, legs, chest, abdomen or back

          -  No serious health conditions that may interfere with the study

          -  Written informed consent

        Exclusion Criteria:

          -  Eczematous regions exclusively in intertriginous areas or in the face

          -  Use of topical steroids or any other dermatologic drug therapy (moisturising creams
             allowed) in the study area or light therapy within the preceding 2 weeks

          -  Use of oral steroids within 1 month prior to the study

          -  Use of concurrent medication e.g. medication that may interfere with the study related
             activities

          -  Factors suggesting low compliance with study procedures

          -  Possible allergy to ingredients in the study medications

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berit Berne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudkliniken, Akademiska sjukhuset, Uppsala</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nacka hudmottagning</name>
      <address>
        <city>Nacka</city>
        <zip>13183</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nacka närsjukhus</name>
      <address>
        <city>Nacka</city>
        <zip>13183</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophiahemmet</name>
      <address>
        <city>Stockholm</city>
        <zip>11486</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudkliniken, Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Läkarhuset Vällingby</name>
      <address>
        <city>Vällingby</city>
        <zip>16862</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>October 10, 2008</last_update_submitted>
  <last_update_submitted_qc>October 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Berit Berne</name_title>
    <organization>Hudkliniken, Akademiska sjukhuset, Uppsala</organization>
  </responsible_party>
  <keyword>Atopic eczema</keyword>
  <keyword>Topical corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

